GlassScriptPhysician profile
Wei Xiong
NPI 1487706610
$3,518.26
in general payments reported to CMS, 2019-2025
26 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $56.02 · 2021: $191 · 2022: $418 · 2023: $520 · 2024: $927 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,469.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $913.79 | 2019-2025 | Briviact, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $460.20 | 2021-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $241.58 | 2021-2025 | Wainua, Andexxa |
| Lilly USA, LLC | $237.34 | 2023-2025 | Amyvid, Kisunla, Reyvow |
| Genentech USA, INC. | $228.43 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Pfizer INC. | $178.82 | 2024-2025 | |
| Amgen INC. | $173.70 | 2019-2025 | Uplizna |
| Averitas Pharma INC. | $166.66 | 2023-2025 | Qutenza |
| Jazz Pharmaceuticals INC. | $155.71 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.97 | 2022-2025 | Hyqvia |
| Argenx US, INC. | $83.74 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $81.95 | 2025 | |
| Csl Behring | $75.82 | 2019-2025 | Kcentra, Privigen |
| Biohaven Pharmaceutical Holding Company LTD. | $75.39 | 2022 | |
| Portola Pharmaceuticals, LLC | $53.39 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $49.44 | 2019-2020 | |
| Neurelis, INC. | $45.10 | 2024-2025 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $32.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.72 | 2019-2023 | Ponvory |
| Lundbeck LLC | $21.97 | 2025 | Vyepti |
| Chiesi USA, INC. | $21.48 | 2024 | Cleviprex |
| Abbott Laboratories | $19.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.99 | 2025 | Austedo Xr |
| Emd Serono, INC. | $16.98 | 2022 | |
| Tanabe Pharma America, INC. | $13.67 | 2025 | Radicava |
| Vertical Pharmaceuticals, LLC | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Xiong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.